Seth Lederman, Tonix Pharmaceuticals CEO

Tonix's lead drug fails PhI­II again, send­ing stock even clos­er to ze­ro

When lit­tle Tonix Phar­ma­ceu­ti­cals re­vealed last Ju­ly that its lead drug failed an in­ter­im analy­sis in fi­bromyal­gia — so much so that out­side da­ta mon­i­tors rec­om­mend­ed halt­ing the tri­al it would un­like­ly pass muster — the com­pa­ny de­cid­ed to go ahead and fol­low pa­tients al­ready on the drug.

So it’s lit­tle sur­prise that TNX-102 flat out failed the fi­nal analy­sis of the Phase III RAL­LY study too, miss­ing sta­tis­ti­cal sig­nif­i­cance over place­bo on the pri­ma­ry end­point of re­duc­tion in dai­ly pain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.